Table 3 False-positive reportprobability values for associations between CASP7 genotypes and cervicalcancer risk

Genotypes	Positive OR (95% CI)*	P*	Statistical power**	Prior probability
Genotypes	Positive OR (95% CI)*	P*	Statistical power**	0.25	0.1	0.01	0.001	0.0001
rs4353229
TT vs. CT/CC
All patients	1.20 (1.02–1.40)	0.026	0.998	0.072	0.190	0.721	0.963	0.996
Postmenopausal	1.39 (1.06–1.82)	0.019	0.722	0.073	0.191	0.723	0.963	0.996
rs10787498
GT vs. TT
All patients	1.19 (1.01–1.40)	0.038	0.999	0.102	0.255	0.790	0.974	0.997
GT/GG vs. TT
Age at primiparity ≤ 24	1.45 (1.13–1.85)	0.003	0.608	0.015	0.043	0.328	0.831	0.980
Tumor size <4 cm	1.21 (1.02–1.44)	0.033	0.993	0.091	0.230	0.767	0.971	0.997
rs1127687
AG/AA vs. GG
FIGO stage II	1.26 (1.02–1.55)	0.031	0.952	0.089	0.227	0.763	0.970	0.997
Combined effect of putative risk genotypes
4 vs. ≤ 3	1.62 (1.14–2.30)	0.007	0.326	0.060	0.162	0.680	0.955	0.995
rs10787498 - rs4353229 joint effect
GT/GG-TT vs. TT-CC/CT	1.33 (1.09–1.63)	0.005	0.983	0.017	0.048	0.357	0.848	0.982
GT/GG-TT vs. others	1.34 (1.11–1.62)	0.002	0.888	0.007	0.020	0.182	0.692	0.957
rs1127687 - rs12247479 joint effect
AG/AA-AG/AA vs. GG-GG	1.56 (1.09–2.23)	0.015	0.414	0.098	0.246	0.782	0.973	0.997
AG/AA-AG/AA vs. others	1.57 (1.11–2.22)	0.012	0.404	0.082	0.211	0.746	0.967	0.997
rs1127687 - rs10787498 joint effect
AG/AA-GT/GG vs. GG-TT	1.58 (1.19–2.11)	0.002	0.369	0.016	0.047	0.349	0.844	0.982
AG/AA-GT/GG vs. others	1.58 (1.21–2.07)	0.001	0.362	0.008	0.024	0.215	0.734	0.965

OR,odds ratio; CI, confidence interval; SCC, squamous cell carcinoma; FIGO, InternationalFederation of Gynecology and Obstetrics; LN, Lymph Node; LVSI, lymph-vascularspace invasion; ER, estrogen receptor; PR, progesterone receptor.
*CrudeOR and P value;
**Statisticalpower was calculated using the number of observations in the subgroup andthe ORs and P values in this table.
Theresults in false-positive report probability analysis were in bold, if theprior probability < 0.20.

Search